Skip to main content
Premium Trial:

Request an Annual Quote

Swift Biosciences Raises $3M in Series A Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Swift Biosciences announced on Wednesday the recent completion of a $3 million Series A financing round led by venture firm DFJ Mercury.

Also participating in the round were several unnamed Michigan-based individual investors who provided seed funding to Swift when it launched in January. The company also said that Daniel Watkins, a managing director at DFJ Mercury, is joining Swift's board.

In a statement, Swift CEO David Olson said that the funding will help accelerate product development and customer testing.

Based in Ann Arbor, Mich., Swift develops molecular biology reagents for research and diagnostic applications. The company said that its products will provide customers "with powerful new ways to examine disease-related genes." It added that it also aims to help quicken the analysis time for samples and at higher volume, while lowering price per sample.

Swift's products are designed so they can be used with a researcher's current instrumentation, it said.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.